NCT07373457 is a Phase 1 clinical trial of HW201877 capsules in Healthy Participants, sponsored by Wuhan Humanwell Innovative Drug Research and Development Center Limited Company.

What drugs are being tested in NCT07373457?

Interventions in NCT07373457: HW201877 capsules, Placebo.

What condition does NCT07373457 study?

NCT07373457 studies Healthy Participants, IBD (Inflammatory Bowel Disease).

Is NCT07373457 still recruiting?

NCT07373457 is currently recruiting now. Last updated 19 January 2026.

Last reviewed 2026-01-19 · How we verify

NCT07373457

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single-Center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, PK/PD, Food Effect of HW201877 in Healthy Volunteers.

Recruiting now Phase 1 Last updated 19 January 2026

What this trial tests

Phase 1 trial testing HW201877 capsules in Healthy Participants in 104 participants. Currently enrolling.

Timeline

26 June 2025

Primary endpoint
1 March 2026

1 March 2026

Quick facts

Lead sponsor	Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	104
Start date	26 June 2025
Primary completion	1 March 2026
Estimated completion	1 March 2026
Sites	1 location across China

Drugs / interventions tested

HW201877 capsules — full drug profile →
Placebo

Conditions studied

Healthy Participants — all drugs for Healthy Participants →
IBD (Inflammatory Bowel Disease) — all drugs for IBD (Inflammatory Bowel Disease) →

Sponsor

Wuhan Humanwell Innovative Drug Research and Development Center Limited Company — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Participants or IBD (Inflammatory Bowel Disease). Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The number and severity of treatment emergent adverse events (TEAEs)
Time frame: Day 1 to Day 5
To assess the safety and tolerability of single or multiple oral dose of HW201877 in healthy adult volunteers

Sponsor's own description

This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single ascending dose (Part 1), which includes a single-dose, two-period crossover FE cohort; (2) a multiple ascending dose (Part 2).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other Wuhan Humanwell Innovative Drug Research and Development Center Limited Company trials

Trials by the same sponsor.

NCT07413328 — HWS116 Monotherapy in Patients With Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT06882135 — HW071021 Monotherapy in Patients With Advanced Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07373457 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Last refreshed: 19 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07373457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing